Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma-Reference-Cited by-同舟云学术

Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma

Published:2021 Issue: Volume: Page:
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Takahashi Naoki¹,Tsukasaki Kunihiro¹,Tanae Ken¹,Kohri Mika¹,Asou Chie¹,Okamura Daisuke¹,Ishikawa Maho¹,Maeda Tomoya¹,Kawai Nobutaka¹,Matsuda Akira¹,Sato Tsugumi²,Kayano Hidekazu²,Arai Eiichi²,Asou Norio¹

Affiliation:

1. Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,

2. Department of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/advpub/0/advpub_21018/_pdf

Reference21 articles.

1. 1 Hirschberg E, Gellhorn A, Gump WS. Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl)amino-methyl]benzimidazole, and of other 2-chloroethyl compounds. Cancer Res. 1957; 17: 904-910.

2. 2 Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14: 309-317.

3. 3 Ohmachi K, Ando K, Ogura M et al.. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010; 101: 2059-2064.

4. 4 Rummel MJ, Niederle N, Maschmeyer G et al. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381: 1203-1210.

5. 5 Rummel M, Kaiser U, Balser C et al. Study Group Indolent Lymphomas. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016; 17: 57-66.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bendamustine and rituximab is well‐tolerated and efficient in the treatment of indolent non‐Hodgkin ' s lymphoma and mantle cell lymphoma in elderly: A single center observational study;International Journal of Cancer;2022-12-30